Merck Animal Health moves to acquire poultry agtech firm TARGAN
Bottom line
Merck Animal Health said on June 11, 2026, that it has signed a definitive agreement to acquire TARGAN, a privately held Raleigh, North Carolina-based animal agtech company focused on hatchery biodevices for poultry production. Financial terms weren’t disclosed. Merck said the deal is expected to close in the third quarter of 2026, pending regulatory approvals and other customary conditions. The acquisition would add TARGAN’s WingScan automated chick-sexing platform, which Merck said can process up to 160,000 chicks per hour, as well as a high-speed ocular spray system designed to deliver vaccines to day-old chicks. (uk.marketscreener.com)
Why it matters: For veterinary professionals working with poultry systems, this deal signals Merck’s push beyond biologics alone and further into hatchery automation, data capture, and device-enabled vaccine delivery. TARGAN has recently been scaling WingScan globally and said in late 2025 that it was processing more than 30 million chicks per week, while also advancing vaccine-delivery technology toward a 2026 launch. That combination could give Merck tighter integration between its poultry vaccine portfolio and hatchery-side hardware, with implications for labor efficiency, chick handling, biosecurity, and how flock-health interventions are delivered at scale. (feedstuffs.com)
What to watch: Watch for regulatory clearance, closing in Q3 2026, and how quickly Merck moves to pair TARGAN’s hatchery devices with its broader poultry health portfolio. (uk.marketscreener.com)
Merck Animal Health is moving deeper into poultry production technology with a deal to acquire TARGAN, a privately held developer of hatchery biodevices and automation systems. The company announced June 11, 2026, that it has signed a definitive agreement for the acquisition, with closing expected in the third quarter of 2026, subject to regulatory approvals and customary conditions. Terms were not disclosed. (uk.marketscreener.com)
The move fits a broader pattern for Merck Animal Health, which has been investing in scale, manufacturing, and livestock growth platforms. Merck’s 2025 annual report said Animal Health generated $6.4 billion in 2025 sales, and livestock products remain a major part of the business. The company has also been expanding through acquisitions, including the 2024 purchase of Elanco’s aqua business, underscoring an appetite for platform-building in food-animal health. (merck.com)
What TARGAN brings is more specific than a conventional product tuck-in. Merck said the deal would broaden its poultry portfolio with WingScan, an automated chick-sexing system that uses vision technology and proprietary algorithms to identify and sort chicks by gender, with throughput of up to 160,000 chicks an hour. It also highlighted TARGAN’s high-speed precision ocular spray platform for administering respiratory and coccidiosis vaccines to day-old chicks, plus future biodevice potential in poultry and other livestock species. Merck Animal Health President Rick DeLuca said the technology complements and accelerates the company’s growing poultry biopharmaceutical business. (uk.marketscreener.com)
TARGAN had already been building commercial momentum before the deal. In December 2025, the company announced a $100 million financing agreement with Symbiotic Capital, saying the funding would support expansion of WingScan and new product launches in 2026-27. At that time, TARGAN said WingScan was processing more than 30 million chicks each week worldwide, revenue had more than doubled from 2024 to 2025, and new technologies for poultry vaccine delivery were advancing toward market. Separate industry coverage around IPPE 2026 said more than 50 WingScan systems had been installed by the end of 2025 and described the vaccine-delivery platform as being in final development and field-trial stage, with commercial launch expected in 2026. (feedstuffs.com)
Public reaction so far has been limited mostly to company statements and trade coverage, but those statements point to the strategic rationale. DeLuca framed the acquisition as a way to add “best-in-class” hatchery biodevice technology to Merck’s poultry business, while TARGAN founder and CEO Ramin Karimpour said Merck had been a foundational partner since TARGAN’s inception and that Merck’s infrastructure should help scale deployment alongside its vaccine portfolio. That language suggests this was as much about commercialization reach as about the underlying devices themselves. (uk.marketscreener.com)
Why it matters: For veterinarians and allied professionals in poultry production, the significance is less about headline M&A and more about convergence. Hatchery automation, chick-sexing, and precision vaccine delivery have typically sat adjacent to animal health, not squarely inside it. By bringing TARGAN in-house, Merck appears to be betting that hardware, software, biologics, and hatchery workflow will increasingly be sold as an integrated system. If that plays out, veterinary teams may see changes in how vaccination protocols are operationalized, how hatchery data are captured and used, and how producers evaluate labor, welfare, consistency, and throughput in early-life flock management. That could also strengthen Merck’s position with integrated poultry companies that want fewer vendors and tighter coordination across production stages. This is an inference based on Merck’s stated strategy and TARGAN’s existing platform footprint. (uk.marketscreener.com)
What to watch: The immediate next step is regulatory review and expected closing in Q3 2026. After that, the key questions will be whether Merck keeps TARGAN’s platform roadmap moving on schedule, how the ocular vaccine-delivery technology is commercialized, and whether the company extends the biodevice model beyond poultry into other livestock categories, as both Merck and TARGAN have suggested is possible. (uk.marketscreener.com)